Gabi Dachs
Gabi Dachs | |
|---|---|
| Academic background | |
| Alma mater | University of Cape Town |
| Thesis | |
| Valerie Abratt | |
| Academic work | |
| Institutions | University of Otago, Medical Research Council Harwell, Oxford Institute for Radiation Oncology |
Gabriele Ursula Dachs is a New Zealand academic, and is a full professor at the University of Otago, specialising in the how cancer cells respond to hypoxia, and developing novel treatments for cancer.
Early life and education
[edit]Dachs was born and raised in Namibia. Dachs completed a Bachelor of Science at the University of Cape Town in South Africa, followed by a PhD titled The effect of metronidazole on Bacteroides fragilis and Escherichia coli at the same institution.[1][2][3]
Academic career
[edit]After conducting postdoctoral research at MRC Harwell in the United Kingdom, Dachs joined the Gray Cancer Institute in London as a senior scientist. She then moved to New Zealand, where she joined the faculty of the Department of Pathology at the University of Otago, becoming a research associate professor in 2015 and then full professor in 2023.[4][5]
Dachs works in the Mackenzie Cancer Research Group and is based at Otago's Christchurch campus.[6][1] She is interested in the molecular mechanisms that make cancers difficult to treat and in developing new treatments.[1] Dachs has explored how cancer cells respond to hypoxia (low oxygen levels) and how the hypoxic pathway is affected by vitamin C.[7][8] Dachs led research that showed that cancer cells from colon tumours removed during surgery retained vitamin C if the patient had received a very high dose infusion of vitamin C before their surgery.[8] Previous work by her group had found that vitamin C might be an effective anticancer agent, but as solid tumours have 'disorganised' blood flow, it was not clear if vitamin C would reach or be retained in tumour cells.[8] Dachs is also interested in why obese cancer patients do less well in treatment, and whether molecular causes for this can be identified.[1] She is also looking at how to improve cancer treatment using prodrugs and gene therapy.[1] Her research spans cell culture, rodent models, and clinical trials in cancer patients.[3]
Honours and awards
[edit]In 2021 Dachs was awarded the University of Otago Christchurch Research Gold Medal.[5]
Selected works
[edit]- Chris P. Guise; Maria R Abbattista; Rachelle S Singleton; et al. (9 February 2010). "The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3". Cancer Research. 70 (4): 1573–1584. doi:10.1158/0008-5472.CAN-09-3237. ISSN 0008-5472. PMID 20145130. Wikidata Q34097892.
- Kaye J Williams; Brian Telfer; Dia Xenaki; et al. (18 April 2005). "Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1". Radiotherapy and Oncology. 75 (1): 89–98. doi:10.1016/J.RADONC.2005.01.009. ISSN 0167-8140. PMID 15878106. Wikidata Q47801291.
- Gabi U Dachs; Joanna Tupper; Gillian M Tozer (1 April 2005). "From bench to bedside for gene-directed enzyme prodrug therapy of cancer". Anti-Cancer Drugs. 16 (4): 349–359. doi:10.1097/00001813-200504000-00001. ISSN 0959-4973. PMID 15746571. Wikidata Q36061340.
- Caroline Kuiper; Ilona G M Molenaar; Gabi U Dachs; Margaret J Currie; Peter H Sykes; Margreet C M Vissers (22 June 2010). "Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer". Cancer Research. 70 (14): 5749–5758. doi:10.1158/0008-5472.CAN-10-0263. ISSN 0008-5472. PMID 20570889. Wikidata Q43008648.
- Margret C M Vissers; Sarah P Gunningham; Mary J Morrison; Gabi U Dachs; Margaret J Currie (30 November 2006). "Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate". Free Radical Biology and Medicine. 42 (6): 765–772. doi:10.1016/J.FREERADBIOMED.2006.11.023. ISSN 0891-5849. PMID 17320759. Wikidata Q40167157.
- Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam Patterson (10 November 2009). "Bystander or no bystander for gene directed enzyme prodrug therapy". Molecules. 14 (11): 4517–4545. doi:10.3390/MOLECULES14114517. ISSN 1420-3049. PMC 6255103. PMID 19924084. Wikidata Q37634940.
- Caroline Kuiper; Gabi U. Dachs; Margaret J. Currie; Margreet C M Vissers (April 2014). "Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response". Free Radical Biology and Medicine. 69: 308–317. doi:10.1016/J.FREERADBIOMED.2014.01.033. ISSN 0891-5849. PMID 24495550. Wikidata Q59617798.
References
[edit]- ^ a b c d e Mackenzie Cancer Research Group (15 February 2023). "Professor Gabi Dachs". www.otago.ac.nz. Retrieved 1 May 2024.
- ^ Dachs, Gabriele Ursula (1992). The effect of metronidazole on Bacteroides fragilis and Escherichia coli (PhD thesis). hdl:11427/18281.
- ^ a b Otago, University of (15 March 2023). "Inaugural Professorial Lecture – Professor Gabi Dachs". www.otago.ac.nz. Retrieved 1 May 2024.
- ^ Otago, University of (29 January 2015). "Otago announces professorial promotions". www.otago.ac.nz. Retrieved 29 April 2024.
- ^ a b University of Otago, Wellington (16 December 2022). "Otago announces 39 new professors". www.otago.ac.nz. Retrieved 29 April 2024.
- ^ Mackenzie Cancer Research Group (5 August 2021). "About the Mackenzie Cancer Research Group". www.otago.ac.nz. Retrieved 1 May 2024.
- ^ "Putting Science Between the Hype and Reality about Vitamin C and Cancer". www.cancerresearchtrustnz.org.nz. Retrieved 1 May 2024.
- ^ a b c "Vitamin C infusions retained by cancerous tumours, new study shows". New Zealand Doctor. 19 May 2024. Retrieved 1 May 2024.
External links
[edit]- The Science Of... Vitamin C, Gabi Dachs on Radio New Zealand in 2017
- Scatterlings: Cancer research across continents and time, Inaugural professorial lecture by Gabi Dachs, 4 May 2023, via YouTube